527 results on '"Schönland, Stefan"'
Search Results
2. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
3. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
4. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
5. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
6. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis
7. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
8. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
9. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
10. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
11. Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information
12. Search for AL amyloidosis risk factors using Mendelian randomization
13. Systemic Light Chain Amyloidosis
14. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
15. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study
16. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
17. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
18. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
19. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY
20. S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
21. P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
22. Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
23. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
24. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
25. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
26. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients
27. CMR 3-102 - Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information
28. Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma
29. Premature Telomeric Loss in Rheumatoid Arthritis Is Genetically Determined and Involves Both Myeloid and Lymphoid Cell Lineages
30. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
31. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
32. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
33. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
34. Quality of Life and Symptoms Among Patients With Relapsed/Refractory AL Amyloidosis Treated With Ixazomib‐Dexamethasone Versus Physician's Choice
35. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT
36. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study
37. Correction:An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-01999-1)
38. Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
39. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
40. Deferred autologous stem cell transplantation in systemic AL amyloidosis
41. 593 PRESENTATION AND OUTCOME OF PATIENTS WITH COEXISTING CARDIAC AL AND ATTR AMYLOIDOSIS
42. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
43. Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
44. International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
45. Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
46. A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
47. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
48. Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report
49. Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images—reference values and performance in patients with heart failure and left ventricular hypertrophy
50. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.